- Home
- Companies
- north america
- antigen presenting
Show results for
Refine by
Antigen Presenting Suppliers In North America
24 companies found
based inOxford, UNITED KINGDOM
ProImmune’s mission is to be your partner of choice for understanding and managing adaptive immune responses. We offer unique solutions for preclinical and clinical immunology research, including a comprehensive and integrated antigen ...
Pro5® MHC Class I Pentamers the most consistent, most published commercial technology for detecting antigen-specific CD8+ T cells. Pro5® MHC Pentamer. The beautiful rational design of Pro5® MHC Pentamers ...
based inCambridge, MASSACHUSETTS (USA)
Sumitomo Pharma Oncology, Inc. is a developer of novel cancer therapeutics based in the U.S. and a wholly owned subsidiary of Sumitomo Pharma Co., Ltd. This U.S. entity, together with the oncology research and development teams in Japan, Cancer ...
based inHouston, TEXAS (USA)
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) is a public biopharmaceutical company based in the Houston, TX area that is developing GP2, a novel peptide immunotherapy, and has commenced a Phase III clinical trial, called Flamingo-01. GP2 is derived ...
Cancer Immunotherapies are a New Method of Cancer Treatment. Among the more established treatment options, such as surgery, chemotherapy, targeted therapy, and radiation therapy, cancer immunotherapy is a rapidly emerging and important field. It ...
based inMonmouth Junction, NEW JERSEY (USA)
MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet ...
Odanacatib (MK-0822) is a potent and selective inhibitor of cathepsin K, with an IC50 of 0.2 nM for human cathepsin ...
based inRaleigh, NORTH CAROLINA (USA)
Kaio's strategy is to develop and in-license technologies and therapies that enable the body’s own immune system to work more efficiently. The goal is to improve clinical outcomes for patients, increase the number and efficacy of therapeutic options ...
based inChatham, NEW JERSEY (USA)
Tonix is a clinical-stage biopharmaceutical company focused on developing novel therapies and vaccines to prevent and treat central nervous system disorders, immunology conditions, infectious diseases, and rare diseases. At Tonix, we are focused on ...
TNX-1850 is the planned new version of the TNX-1800 vaccine that encodes spike protein from SARS-CoV-2 BA.2 ...
based inWest Vancouver, BRITISH COLUMBIA (CANADA)
Focusing initially on breast cancer, BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX:BCT) is dedicated to enhancing the lives of people with cancer with limited therapy options by developing novel immunotherapies to fight cancer. ...
We believe that Bria-IMT™/Bria-OTS™, activates the patient’s immune system to recognize tumor cells and destroy them. We hypothesize that Bria-IMT™/Bria-OTS™, exert their action by stimulating the ...
based inPalo Alto, CALIFORNIA (USA)
Immune-Onc is a clinical-stage company developing a novel class of myeloid checkpoint inhibitors. We believe myeloid checkpoints are the next frontier of immunotherapy for cancer. In collaboration with scientists, our research team is among the ...
Immune-Onc’s lead program is IO-202, an antagonist antibody targeting the myeloid checkpoint LILRB4 (also known as ILT3). Immune-Onc has a Phase I trial underway to evaluate IO-202 as a potential treatment for acute myeloid leukemia (AML) and ...
based inLoveland, COLORADO (USA)
Through innovation, invention, and strategic partnerships with worldwide leaders in diagnostics and treatments, Heska provides the benefits of latest generation technologies to pet healthcare providers. Heska’s range of complete blood diagnostic ...
based inUtrecht, NETHERLANDS
At LAVA, we are focused on applying our expertise in gamma-delta T cell engagers. We are building a pipeline of gamma-delta bsTCEs that have applications in both solid and hematologic malignancies. Our lead program, LAVA-051, targets the tumor ...
Vγ9Vδ2 T cells belong to the first line of defense against cancer and have the potential to elicit deep and durable responses in the ...
based inIrving, TEXAS (USA)
Optimum Therapeutic Solutions is a visionary leader in nutrient and supplement solutions. Recognizing a need for a line of nutritional supplements designed by health care professionals, for health care professionals, Optimum Therapeutic Solutions ...
S-Acetyl Glutathione is an acetylated form of glutathione. This form is well-absorbed and more stable throughout the digestive tract than other forms on the market. Use of stomach acid-resistant capsules further protect stability. Laboratory data ...
based inGaithersburg, MARYLAND (USA)
NexImmune is a clinical-stage biotechnology company developing unique approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation (AIMâ„¢) technology. AIM nanoparticles act as synthetic dendritic cells to deliver ...
The injectable modality (AIM INJ) is an injectable pharmaceutical product of AIM nanoparticles decorated with antigen-specific peptides and co-stimulatory molecules appropriate for the disease being targeted. Based on specific size and ...
based inMinneapolis, MINNESOTA (USA)
Bio-Techne empowers researchers in Life Science and Clinical Diagnostics by providing high-quality reagents, instruments, custom manufacturing, and testing services. Our family of brands creates a unique portfolio of products and services. Science ...
Immune cell therapy is rapidly emerging as an important alternative for cancer treatment, as well as treatment of autoimmune disease. Also known as adoptive cell therapy or cellular immunotherapy, it supercharges an individual’s immune ...
based inVienna, AUSTRIA
Hookipa Pharma Inc. is a clinical-stage biopharmaceutical company developing a new class of immunotherapeutics based on a proprietary arenavirus platform that is designed to reprogram the body’s immune system. We are using our non-replicating and ...
The immune system is the body’s natural defense mechanism against pathogens. Our proprietary technology is capable of targeting and treating disease with a tailored immune response. Our science is based on a novel and highly differentiated ...
based inHolliston, MASSACHUSETTS (USA)
BTX has been at the forefront of electroporation technology since we introduced the first commercially available electroporator in 1983. For over 30 years, we have made it our priority to focus only on electroporation and electrofusion. This focus ...
The AgilePulse In Vivo System, used for animal immunization, vaccine development, and gene therapy, provides an intra-muscular, intra-dermal, or intra-tumor electroporation solution to produce maximum transfection efficiency. Traditional in vivo ...
based inMenlo Park, CALIFORNIA (USA)
Adicet is a biotechnology company engaged in the development of first-in-class off-the-shelf allogeneic gamma delta T cell therapies for cancer and other diseases. Adicet has developed a proprietary cell platform process to activate, engineer and ...
Gamma delta T cells represent a new generation of universal cell therapy. The current engineered autologous alpha beta T cell products have shown significant efficacy in hematological malignancies; however comparable efficacy in solid tumors is yet ...
based inBerlin, GERMANY
T-knife Therapeutics is a biopharmaceutical company dedicated to developing novel therapeutics to fight cancer. The company is initially focused on T cell receptor (TCR) engineered T cell therapies (TCR-Ts), a promising modality that holds the ...
based inSan Diego, CALIFORNIA (USA)
Brooklyn ImmunoTherapeutics (BTX) is a clinical-stage biopharmaceutical company committed to creating a world where patients and families with high unmet medical needs have access to effective treatments. We are pioneers in using the latest ...
Why human derived? Brooklyn has developed a powerful method to create complex cytokine mixtures derived from a human source. Cytokines are powerful immune factors that play an essential role in T cell signaling, activation, proliferation, and ...
based inWayne, PENNSYLVANIA (USA)
Sino Biological is committed to providing high-quality recombinant protein and antibody reagents and to being a one-stop technical services shop for life science researchers around the world. All of our products are independently developed and ...
FCAR, also called FcαRI or CD89, is a type I transmembrane receptor for Fc region of IgA which is the most abundant immunoglobulin in mucosal areas but is only the second most common antibody isotype in serum. This receptor is present on the ...
based inCarlsbad, CALIFORNIA (USA)
Founded in 1996, IVD Research, Inc. is privately held by Dave Lambillotte, Ann Marie Martin and Christopher Lambillotte. Our tight-knit group of dedicated professionals works well as a team, each bringing their own unique experiences and education ...
Giardiasis, caused by the single-celled Giardia lambliaparasite, is the most common parasitic disease in the United States. As many as 100 million mild infections and 1 million severe infections are reported ...